1. VANCOMYCIN
Mohammed – Alrjoub

2.  General info
 Clinical info
1- indications
2- dosage and administration
3- CI
4- DI
5- precautions
 Pharmaceutical info: dosage forms and storage
conditions

3. GENERAL INFORMATION
 MOA: Cell wall synthesis inhibitor
 Antibacterial spectrum: G+ organisms ( most
important MRSA and drug resistant enterococci)

4. CLINICAL INFO:
INDICATION
 For serious G+ infections or those who have an
allergy to penicillin
 MRSA and MRSE
 Orally for life threatening Clostridium Difficile
associated colitis
 With aminoglycosides for enterococcal endocarditis

5. CLINICAL INFO:
DOSAGE AND ADMINISTRATION
 By slow iv infusion over 60-90 min depending on
dose
a. 500mg q.6.h over 1h or 1g bid over 100min
b. at a rate no more than 10mg/min
 Preferred to be intermittent iv inf.
 Dose depends on CLcr , age, and B.wt.

6. CLINICAL INFO:
DOSAGE AND ADMINISTRATION
 Preparation:
1- Add 10 ml of sterile WFI to a 500 mg vial of
Vancomycin powder >> 50 mg/ml
2- Reconstituted solutions containing 500 mg vancomycin
must be diluted with at least
100 ml diluent. (NaCl soln. or Dextrose soln.)

7. CLINICAL INFO:
C/I
 History of deafness
 Renal impairment (adjust dose)

8. CLINICAL INFO:
S/E
 Red man syndrome: flushing and shock if infused
rapidly
 Ototoxicity
 Nephrotoxicity
 Fever ,chills and phlebitis

9. CLINICAL INFO:
DI
 Aminoglycosides, furosemide
 Anesthetics: hypersensitivity

10. PRECAUTIONS
 Renal impairment
 Rapid infusion
 Monitor renal function and hearing
 Pregnancy: BM
 Breast feeding: oral absorption is poor but problems
with bowels normal flora and allergic effects have
been reported

11. PHARMACEUTICAL INFO:
DOSAGE FORM AND STORAGE CONDITIONS
 Vancocin
 Vancoled
500 mg vial
 Store in airtight container and protect from light

12. TEICOPLANIN

13. GENERAL INFORMATION
 Glycopeptide antibiotic
 MOA: Cell wall synthesis inhibitor
 Antibacterial spectrum: G+ organisms ( most
important MRSA and drug resistant enterococci)

14. CLINICAL INFO:
INDICATION
 For serious G+ infections or those who have an allergy
to penicillin
 MRSA and MRSE
 Orally for life threatening Clostridium Difficile associated
colitis
 For endocarditis
 Treating infection of the abdominal cavity (peritonitis)
associated with peritoneal dialysis.

15. CLINICAL INFO:
DOSAGE AND ADMINISTRATION
 ROA: Intraperitoneally, IM, IV (inf and bolus), po
 Given once daily after the loading dose
 Dose depends on age, CLcr, and wt

16. CLINICAL INFO:
DOSAGE AND ADMINISTRATION
 Preperation:
1- add water from the ampoule into the vial (3ml)
2- rotate gently between hands to dissolve the
powder be careful not to form foam…. If foam
develops leave the soln to stand for 15min
3- dilute with NaCl soln, Lactate Ringers, or
Dextrose soln or NaCl with dextrose soln.
4- add lidocaine 0.5 or 1% if IM
** the final soln. is stable for about 24hrs at 2-8◦ c
(beware of contamination)

17. CLINICAL INFO:
C/I
 Hypersensitivity
 Renal impairment (adjust dose)

18. CLINICAL INFO:
S/E
 Common: pain, fever, rash, itching, redness of skin,
NVD
 Hearing loss and balance disorders
 Liver and kidney function changes
 Rare: change in blood cell count

19. CLINICAL INFO:
DI
 Aminoglycosides
 furosemide
 Amphotericin B
 Cyclosporine

20. PRECAUTIONS
 Renal impairment
 Allergy to vancomycin (cross-allergy)
 Monitor renal function, liver function,hearingand
blood
 Superinfection
 Pregnancy, breast feeding: unknown
 Contains 24.8mg Na

21. PHARMACEUTICAL INFO:
DOSAGE FORM AND STORAGE CONDITIONS
 Targocid (Sanofi Aventis)
200,400 mg vial
 Store under 25◦ c